This response is comparable to that achieved using topical steroids. Sectors of plaque receiving drug alone or light alone exhibited no statistically significant effect when compared to the untreated area. PH-10 therapy was painless, with no serious local or systemic acute side effects, in sharp contrast to most other therapeutic options for patients with severe psoriasis. Responses were objectively measured using ultrasound imaging thirty days after a single treatment regimen. This appears to result in progressive improvement of symptoms.
Psoriasis is a chronic, recurrent disease of the skin.
It typically appears as well defined, dry lesions with large silvery scales and marked redness. Its cause is unknown. About 150,000 to 260,000 new cases are diagnosed annually. Photogen develops innovative therapeutic and diagnostic products using proprietary drugs and advanced energy sources. In addition to the use of PH-10 as a treatment for psoriasis, it also shows promise as a treatment for other topical disorders and for certain cancer tumors.